Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
ABSTRACT ACCEPTED FOR POSTER PRESENTATION AT THE SOCIETY FOR
IMMUNOTHERAPY OF CANCER ANNUAL MEETING
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) today announced that the
abstract entitled, Trial evaluating overall survival in epithelial ovarian cancer (EOC) patients in second remission with an autologous dendritic cell therapy targeting mucin 1 has been accepted for a poster presentation at the Society
for Immunotherapy of Cancer ( SITC ) 29th Annual Meeting.
The poster will be presented by
Prima s Chief Technical Officer, Dr. Sharron Gargosky, at the Gaylord National Hotel and Convention Center in National Harbor, MD. Poster presentations are scheduled to occur on Friday, November 7, 2014 and on Saturday,
November 8, 2014 from 12:30 p.m. 2:00 p.m. The exact time and location of Dr. Gargosky s poster presentation will be available closer to the conference date.
Prima BioMed is a globally active
leader in cancer immunotherapy. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima s lead product is CVac , an autologous
dendritic cell-based product currently in clinical trials. www.primabiomed.com.au
For further information please contact:
Adam Holdsworth, ProActive Capital
+1 (646) 862 4607; adamh@proactivecapital.com
Australia Investor/Media:
Mr Matthew Gregorowski,
Citadel Communications
+61 (0) 422 534 755; mgregorowski@citadelpr.com.au
Europe Investor/Media:
+49 (0) 69 905505-52; amuehlhaus@edicto.de